Response to Comments: Biomarker Testing for Prostate Cancer Diagnosis

This document is a response-to-comments notice regarding the Biomarker Testing for Prostate Cancer Diagnosis Local Coverage Determination and does not contain clinical coverage criteria. It records that the public notice period began on September 15, 2022, and the final LCD became effective November 1, 2022.

"National Government Services solicited public comments on the Biomarker Testing for Prostate Cancer Diagnosis LCD; the official notice period began on 2022-09-15 and the final determination becomes..."

Sign up to see full coverage criteria, indications, and limitations.